Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: Natalizumab Treatment Interruption
NCT01071083Phase 2Completed
- Sponsor
- Biogen
- Start
- Mar 2010
- Primary completion
- Nov 2011
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of natalizumab in multiple sclerosis (MS), sponsored by Biogen. Started Mar 2010; status: completed.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01071083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01071083.